Overview

Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
Phase:
Phase 2
Details
Lead Sponsor:
Revalesio Corporation
Treatments:
RNS60